Compare treatments
Compounded oral GLP-1 tablets vs compounded semaglutide
A daily tablet against a weekly injection: how each one is taken, what the reference label for each reports, and what each costs here.
This page is general information, not medical advice. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality. A qualified clinician determines whether treatment is appropriate for you.
Generated from the family's dataset. No clinician has reviewed this page as a document.
What actually differs
These two are taken differently enough that the practical question is usually not which molecule but which routine: something every day against something once a week. The approved oral product the tablet column cites carries timing rules around food that the weekly injection's label does not, and the prescriber is the one who says how a compounded tablet from here is actually taken.
The rows below set the two side by side on the attributes a prescribing document actually speaks to, and name the document each row came from.
What this page does not tell you
It does not tell you which of the two to take. That is a clinical decision, and it depends on a medical history this page has never seen — which is also why there is no row below the table with a verdict in it.
It also does not report a head-to-head result, because neither reference label carries one against the other medicine named here. The two sets of trial results were measured in different groups of people, over different lengths of time, so reading the columns against each other as a contest reads something into them that the documents do not say.
Every cited row in the tablet column is read from the label of the only approved oral GLP-1 product, which is an oral semaglutide tablet. The tablet program here is a compounded preparation in a different form, and it also covers tirzepatide, for which no oral product is approved and no label exists. Nothing in this column describes what a prescription from this site arrives as. DailyMed, U.S. National Library of Medicine, 2026-08-19
Every cited row in the semaglutide column is read from the label of Wegovy, an approved semaglutide injection. What this site dispenses is a compounded preparation of the same molecule, which is not the product that label describes and was not the product its trials studied. DailyMed, U.S. National Library of Medicine, 2026-06-30
The Rybelsus label reports its results from trials in adults with type 2 diabetes, in trials of the approved oral semaglutide product running 26 weeks or longer. DailyMed, U.S. National Library of Medicine, 2026-08-19
The Wegovy label reports its results from trials in adults with obesity, or with overweight and at least one weight-related condition, treated for 68 weeks. DailyMed, U.S. National Library of Medicine, 2026-06-30
| Attribute | compounded oral GLP-1 tablets | compounded semaglutide |
|---|---|---|
| How it is taken | The approved oral semaglutide label describes a tablet swallowed whole on an empty stomach, with no more than a small sip of plain water, at least 30 minutes before anything else is eaten or drunk. The compounded tablet dispensed here is a different preparation, and the directions that govern it come from the prescriber rather than from that label. DailyMed, U.S. National Library of Medicine, 2026-08-19 | An injection under the skin of the abdomen, thigh or upper arm. DailyMed, U.S. National Library of Medicine, 2026-06-30 |
| How often | The approved oral semaglutide label is a once-daily product, taken every day. No oral tirzepatide product is approved, so the tablet program's other molecule has no published oral schedule of its own. DailyMed, U.S. National Library of Medicine, 2026-08-19 | Once a week, on the same day each week. DailyMed, U.S. National Library of Medicine, 2026-06-30 |
| Published dose escalation | The approved oral semaglutide label starts at 3 mg once daily for 30 days, then moves to 7 mg once daily; after at least a further 30 days the dose may be increased to 14 mg once daily. Nothing equivalent is published for oral tirzepatide, because no oral tirzepatide product is approved. DailyMed, U.S. National Library of Medicine, 2026-08-19 | The label escalates over 16 weeks — 0.25 mg once weekly, then 0.5 mg, then 1 mg, then 1.7 mg, four weeks at each step — before the 2.4 mg maintenance dose. DailyMed, U.S. National Library of Medicine, 2026-06-30 |
| What the reference label reports for tolerability | The approved oral semaglutide label lists nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation among the most common adverse reactions. DailyMed, U.S. National Library of Medicine, 2026-08-19 | The label lists nausea, diarrhea, vomiting, constipation and abdominal pain among the most common adverse reactions. DailyMed, U.S. National Library of Medicine, 2026-06-30 |
| What the reference label is approved for | The approved oral semaglutide product is approved as an addition to diet and exercise to improve blood-sugar control in adults with type 2 diabetes — not for weight management. DailyMed, U.S. National Library of Medicine, 2026-08-19 | The reference product is approved for long-term weight management alongside a reduced-calorie diet and increased physical activity. DailyMed, U.S. National Library of Medicine, 2026-06-30 |
| What it costs here | $129/moBilled monthly on a 6-month plan — for semaglutide — tirzepatide priced separately | $146/moBilled monthly on a 6-month plan |